

Press Release 21 March 2016

Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description

Infant Bacterial Therapeutics AB (publ) ("IBT") has been approved for listing and the company's series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser Bankaktiebolag as Certified Adviser. The listing is part of the distribution of all of BioGaia AB's (publ) shares in IBT to BioGaia's shareholders, which was resolved at the extraordinary general meeting of BioGaia on 18 March 2016.

A company description has been prepared in connection with the listing and is available on IBT's website, www.ibtherapeutics.com

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
info@ibtherapeutics.com

Infant Bacterial Therapeutics AB ("IBT") is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infant. IBT's current focus is on clinical development of IBP-9414, a drug candidate containing *Lactobacillus reuteri*, in the prevention of necrotizing enterocolitis ("NEC"), a fatal disease that affects premature infants.

www.ibtherapeutics.com